Eun Yang
Stock Analyst at Jefferies
(0.53)
# 4,184
Out of 5,150 analysts
31
Total ratings
35.29%
Success rate
-23.05%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals | Upgrades: Buy | $23 → $42 | $29.63 | +41.75% | 1 | Nov 5, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $490.21 | -11.87% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $4.64 | +72.41% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $56 → $12 | $10.51 | +14.23% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $66.54 | -50.41% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.39 | +1,914.39% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $29.98 | -9.94% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.90 | +268.42% | 1 | Feb 10, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $4.12 | +506.80% | 1 | Nov 14, 2022 | |
| NCNA NuCana | Maintains: Buy | $105,000 → $15,000 | $2.13 | +704,125.35% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.49 | +1,577.85% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $26.70 | +31.09% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $379.27 | -41.99% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $189.94 | +63.21% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $148.22 | -46.03% | 3 | Jul 11, 2017 |
Rigel Pharmaceuticals
Nov 5, 2025
Upgrades: Buy
Price Target: $23 → $42
Current: $29.63
Upside: +41.75%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $490.21
Upside: -11.87%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $4.64
Upside: +72.41%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $56 → $12
Current: $10.51
Upside: +14.23%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $66.54
Upside: -50.41%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.39
Upside: +1,914.39%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $29.98
Upside: -9.94%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.90
Upside: +268.42%
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $4.12
Upside: +506.80%
NuCana
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $2.13
Upside: +704,125.35%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.49
Upside: +1,577.85%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $26.70
Upside: +31.09%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $379.27
Upside: -41.99%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $189.94
Upside: +63.21%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $148.22
Upside: -46.03%